Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fortrea Holdings Inc.FTRE · Entity 4623 | General Counsel | September 08, 2025 | September 10, 2025 |
| G1 Therapeutics, Inc.GTHX · Entity 87413 | General Counsel | January 03, 2023 | January 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fortrea Holdings Inc.
Report date September 08, 2025 · Filed September 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,769 |
Reported balance
After 2025-09-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-09-08 · Exercise / conversion · Acquired 5,788 · Balance 20,769 F1: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. |
| Common StockSEC Table I · non-derivative | Direct | 19,092 |
Reported balance
After 2025-09-09 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-09-09 · Sale · Disposed 1,677 · Balance 19,092 F2: The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3: This transaction was executed in multiple trades at prices ranging from $10.02 to $10.44. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4: This number reflects the aggregate amount of Common Stock held by the reporting person. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 47,167 |
Reported balance
After 2025-09-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-09-08 · Exercise / conversion · Disposed 5,788 · Balance 47,167 F1: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F5: The RSUs vested on September 6, 2025. The second installment will vest on September 6, 2026. F6: This number reflects the aggregate number of RSUs held by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date.
F2: The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3: This transaction was executed in multiple trades at prices ranging from $10.02 to $10.44. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This number reflects the aggregate amount of Common Stock held by the reporting person.
F5: The RSUs vested on September 6, 2025. The second installment will vest on September 6, 2026.
F6: This number reflects the aggregate number of RSUs held by the reporting person.
G1 Therapeutics, Inc.
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,455 |
Reported balance
After 2023-01-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 17,900 · Balance 43,455 F1: Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2024 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date. F2: Each RSU represents a contingent right to receive one share of Issuer common stock. F3: Represents (i) 6,680 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; (iii) 12,000 RSUs from award granted on January 3, 2022; and (iv) 17,900 RSUs from award granted on January 3, 2023. |
| Common StockSEC Table I · non-derivative | Direct | 41,816 |
Reported balance
After 2023-01-04 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-01-04 · Sale · Disposed 1,639 · Balance 41,816 F4: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person. F5: The price represents the weighted average price with a low of $5.44 and a high of $5.78. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6: Represents (i) 8,041 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 17,900 RSUs from award granted on January 3, 2023. |
| Common StockSEC Table I · non-derivative | Direct | 41,087 |
Reported balance
After 2023-01-05 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2023-01-05 · Sale · Disposed 729 · Balance 41,087 F4: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person. F7: The price represents the weighted average price with a low of $5.35 and a high of $5.49. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8: Represents (i) 8,687 shares of common stock; (ii) 5,500 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 17,900 RSUs from award granted on January 3, 2023. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.73 · Expires 2033-01-03 | Direct | 35,700 |
Reported balance
After 2023-01-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-01-03 · Grant · Acquired 35,700 · Balance 35,700 F9: The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2024 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
F2: Each RSU represents a contingent right to receive one share of Issuer common stock.
F3: Represents (i) 6,680 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; (iii) 12,000 RSUs from award granted on January 3, 2022; and (iv) 17,900 RSUs from award granted on January 3, 2023.
F4: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
F5: The price represents the weighted average price with a low of $5.44 and a high of $5.78. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: Represents (i) 8,041 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 17,900 RSUs from award granted on January 3, 2023.
F7: The price represents the weighted average price with a low of $5.35 and a high of $5.49. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: Represents (i) 8,687 shares of common stock; (ii) 5,500 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 17,900 RSUs from award granted on January 3, 2023.
F9: The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2025 Filed Sep 10, 2025 16:34 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | SaleCommon Stock | 1,677 | $10.23 | $17,155.71 |
DisclosureSEC source: 0001965040-25-000118 · form4.xml · nonDerivative · entry 2 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,092 F2 · security: The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $10.02 to $10.44. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 16:34 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionRestricted Stock Unit · Derivative | 5,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001965040-25-000118 · form4.xml · derivative · entry 3 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,167 Underlying: Common Stock · 5,788 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F5 · derivative.exercise_date: The RSUs vested on September 6, 2025. The second installment will vest on September 6, 2026. F5 · derivative.expiration_date: The RSUs vested on September 6, 2025. The second installment will vest on September 6, 2026. F6 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 16:34 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionCommon Stock | 5,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001965040-25-000118 · form4.xml · nonDerivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 17:42 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | SaleCommon Stock | 2,191 | $4.17 | $9,136.47 |
DisclosureSEC source: 0001127602-25-016770 · form4.xml · nonDerivative · entry 2 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,981 F2 · security: The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $3.99 to $4.38. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 17:42 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionRestricted Stock Unit · Derivative | 7,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-016770 · form4.xml · derivative · entry 3 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,955 Underlying: Common Stock · 7,706 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F5 · derivative.exercise_date: In connection with the spin-off of Fortrea by Laboratory Corporation of America Holdings ("Labcorp"), RSUs granted by Labcorp were converted into time-vesting RSUs of Fortrea pursuant to the terms of the Employee Matters Agreement. These RSUs vested on June 1, 2025. F5 · derivative.expiration_date: In connection with the spin-off of Fortrea by Laboratory Corporation of America Holdings ("Labcorp"), RSUs granted by Labcorp were converted into time-vesting RSUs of Fortrea pursuant to the terms of the Employee Matters Agreement. These RSUs vested on June 1, 2025. F6 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 17:42 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionCommon Stock | 7,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-016770 · form4.xml · nonDerivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 16:37 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | SaleCommon Stock | 1,007 | $9.70 | $9,767.90 |
DisclosureSEC source: 0001127602-25-009700 · form4.xml · nonDerivative · entry 2 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,466 F2 · security: The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $9.61 to $9.83. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 16:37 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionRestricted Stock Unit · Derivative | 2,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-009700 · form4.xml · derivative · entry 3 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,661 Underlying: Common Stock · 2,998 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F5 · derivative.exercise_date: The RSUs vest in three equal annual installments beginning on March 13, 2025. F5 · derivative.expiration_date: The RSUs vest in three equal annual installments beginning on March 13, 2025. F6 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 16:37 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionCommon Stock | 2,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-009700 · form4.xml · nonDerivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 17:08 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 27,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-008890 · form4.xml · derivative · entry 2 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,659 Underlying: Common Stock · 27,668 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. F4 · derivative.exercise_date: The RSUs vest in three substantially equal annual installments beginning on March 7, 2026. F4 · derivative.expiration_date: The RSUs vest in three substantially equal annual installments beginning on March 7, 2026. F3 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 17:08 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 11,577 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-008890 · form4.xml · derivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,991 Underlying: Common Stock · 11,577 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. F2 · derivative.exercise_date: The RSUs vest in two substantially equal installments on September 6, 2025 and September 6, 2026. F2 · derivative.expiration_date: The RSUs vest in two substantially equal installments on September 6, 2025 and September 6, 2026. F3 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| June 12, 2024 Filed Jun 12, 2024 18:28 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | PurchaseCommon Stock | 2,000 | $25.30 | $50,600.00 |
DisclosureSEC source: 0001127602-24-018484 · form4.xml · nonDerivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,475 F1 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| June 03, 2024 Filed Jun 3, 2024 19:08 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionRestricted Stock Unit · Derivative | 7,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017412 · form4.xml · derivative · entry 3 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,414 Underlying: Common Stock · 7,706 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. F4 · derivative.exercise_date: In connection with the spin-off of Fortrea by Laboratory Corporation of America Holdings ("Labcorp"), RSUs granted by Labcorp were converted into time-vesting RSUs of Fortrea pursuant to the terms of the Employee Matters Agreement. These RSUs vested on June 1, 2024. F4 · derivative.expiration_date: In connection with the spin-off of Fortrea by Laboratory Corporation of America Holdings ("Labcorp"), RSUs granted by Labcorp were converted into time-vesting RSUs of Fortrea pursuant to the terms of the Employee Matters Agreement. These RSUs vested on June 1, 2024. F5 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| June 03, 2024 Filed Jun 3, 2024 19:08 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Tax withholdingCommon Stock | 2,231 | $24.85 | $55,440.35 |
DisclosureSEC source: 0001127602-24-017412 · form4.xml · nonDerivative · entry 2 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,475 F2 · security: Shares withheld by Fortrea to satisfy tax withholding requirements on vesting of RSUs. F3 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| June 03, 2024 Filed Jun 3, 2024 19:08 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionCommon Stock | 7,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017412 · form4.xml · nonDerivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:51 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 8,996 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-010275 · form4.xml · derivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,120 Underlying: Common Stock · 8,996 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs in shares of Common Stock on their scheduled vesting date. F2 · derivative.exercise_date: The RSUs vest in three equal annual installments beginning on March 13, 2025. F2 · derivative.expiration_date: The RSUs vest in three equal annual installments beginning on March 13, 2025. F3 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 18:50 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 20,702 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020281 · form4.xml · derivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,702 Underlying: Common Stock · 20,702 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. F2 · derivative.exercise_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), RSUs granted by Labcorp were converted into time-vesting RSUs of Fortrea pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA. The RSUs vest in three equal annual installments beginning on June 1, 2024. F2 · derivative.expiration_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), RSUs granted by Labcorp were converted into time-vesting RSUs of Fortrea pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA. The RSUs vest in three equal annual installments beginning on June 1, 2024. Read SEC document |
| June 30, 2023 Filed Jul 19, 2023 17:02 UTC Amendment | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 23,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-021030 · form4a.xml · derivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,124 Underlying: Common Stock · 23,124 shares Expires not disclosed F1 · security: This Form 4 is amended to reflect the adjusted amount of Restricted Stock Unit ("RSU") issued to the Reporting Person in connection with the finalization of the adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Laboratory Corporation of America Holdings ("Labcorp"), and Fortrea Holdings Inc. ("Fortrea"). F2 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. F3 · derivative.exercise_date: In connection with the spin-off ("Spin-Off") of Fortrea by Labcorp, RSUs granted by Labcorp were converted into time-vesting RSUs of Fortrea pursuant to the terms of the EMA. The number of RSUs have been adjusted due to the finalization of the adjustment ratio pursuant to the EMA. The RSUs vest in three equal annual installments beginning on June 1, 2024. F3 · derivative.expiration_date: In connection with the spin-off ("Spin-Off") of Fortrea by Labcorp, RSUs granted by Labcorp were converted into time-vesting RSUs of Fortrea pursuant to the terms of the EMA. The number of RSUs have been adjusted due to the finalization of the adjustment ratio pursuant to the EMA. The RSUs vest in three equal annual installments beginning on June 1, 2024. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 16:34 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | OtherCommon Stock | 25 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019157 · form4.xml · nonDerivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: No plan indicated Ownership: Indirect · By Son Disclosed balance after: 25 F1 · kind: In connection with the spin-off of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), Labcorp will distribute all of the outstanding shares of Fortrea common stock held by Labcorp to Labcorp common stockholders as of the record date, which was the close of business on June 20, 2023 (the "Record Date"). For each share of Labcorp common stock held on the Record Date, Labcorp will distribute one share of Fortrea common stock. Read SEC document |
| January 05, 2023 Filed Jan 5, 2023 20:25 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 729 | $5.41 | $3,942.07 |
DisclosureSEC source: 0001562180-23-000250 · primarydocument.xml · nonDerivative · entry 3 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,087 F4 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person. F7 · price: The price represents the weighted average price with a low of $5.35 and a high of $5.49. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · balance_after: Represents (i) 8,687 shares of common stock; (ii) 5,500 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 17,900 RSUs from award granted on January 3, 2023. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 20:25 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 1,639 | $5.58 | $9,138.41 |
DisclosureSEC source: 0001562180-23-000250 · primarydocument.xml · nonDerivative · entry 2 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,816 F4 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person. F5 · price: The price represents the weighted average price with a low of $5.44 and a high of $5.78. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6 · balance_after: Represents (i) 8,041 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 17,900 RSUs from award granted on January 3, 2023. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 20:25 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to buy) · Derivative | 35,700 | $0.00 Strike: $5.73 | $0.00 |
DisclosureSEC source: 0001562180-23-000250 · primarydocument.xml · derivative · entry 4 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,700 Underlying: Common Stock · 35,700 shares Expires 2033-01-03 F9 · derivative.exercise_date: The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 20:25 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantCommon Stock | 17,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000250 · primarydocument.xml · nonDerivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,455 F1 · shares: Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2024 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. F3 · balance_after: Represents (i) 6,680 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; (iii) 12,000 RSUs from award granted on January 3, 2022; and (iv) 17,900 RSUs from award granted on January 3, 2023. Read SEC document |
| January 05, 2022 Filed Jan 5, 2022 20:48 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 1,445 | $10.61 | $15,333.62 |
DisclosureSEC source: 0001562180-22-000309 · primarydocument.xml · nonDerivative · entry 2 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,555 F4 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person. F5 · price: The price represents the weighted average price with a low of $10.45 and a high of $10.76. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6 · balance_after: Represents (i) 5,305 shares of common stock; (ii) 8,250 RSUs from award granted on January 4, 2021; and (iii) 12,000 RSUs from award granted on January 3, 2022. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 20:48 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to buy) · Derivative | 53,000 | $0.00 Strike: $10.69 | $0.00 |
DisclosureSEC source: 0001562180-22-000309 · primarydocument.xml · derivative · entry 3 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 53,000 shares Expires 2032-01-03 F7 · derivative.exercise_date: The shares underlying this option vest as to 25% of the shares on January 3, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 20:48 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000309 · primarydocument.xml · nonDerivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 F1 · shares: Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2023 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. F3 · balance_after: Represents (i) 4,000 shares of common stock; (ii) 11,000 RSUs from award granted on January 4, 2021; and (iii) 12,000 RSUs from award granted on January 3, 2022. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 18:18 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to Buy) · Derivative | 58,000 | $0.00 Strike: $18.07 | $0.00 |
DisclosureSEC source: 0000899243-21-000460 · doc4.xml · derivative · entry 2 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,000 Underlying: Common Stock · 58,000 shares Expires 2031-01-04 F4 · derivative.exercise_date: The shares underlying this option vest as to 25% of the shares on January 4, 2022, with the remainder vesting in 36 equal installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 18:18 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantCommon Stock | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-000460 · doc4.xml · nonDerivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents a restricted stock unit ("RSU") award that vests 25% on January 4, 2022 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. F3 · balance_after: Represents 4,000 shares of common stock and 11,000 restricted stock units. Read SEC document |
| September 04, 2020 Filed Sep 8, 2020 20:38 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | PurchaseCommon Stock | 1,000 | $14.95 | $14,950.00 |
DisclosureSEC source: 0000899243-20-024597 · doc4.xml · nonDerivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 16:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $21.08 | $0.00 |
DisclosureSEC source: 0001562180-20-001008 · primarydocument.xml · derivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-02-06 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% of the shares on February 06, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 02, 2019 Filed Jan 2, 2019 17:29 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $19.56 | $0.00 |
DisclosureSEC source: 0001562180-19-000092 · primarydocument.xml · derivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% of the shares on January 02, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| December 26, 2018 Filed Dec 27, 2018 16:59 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | PurchaseCommon Stock | 1,000 | $18.25 | $18,250.00 |
DisclosureSEC source: 0001562180-18-005115 · primarydocument.xml · nonDerivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| December 10, 2018 Filed Dec 11, 2018 16:08 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | PurchaseCommon Stock | 1,000 | $32.51 | $32,507.90 |
DisclosureSEC source: 0001562180-18-004905 · primarydocument.xml · nonDerivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 16:08 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $47.86 | $0.00 |
DisclosureSEC source: 0001209191-18-039652 · doc4.xml · derivative · entry 1 Hanson James S. · CIK 0001744887 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2028-06-25 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% of the shares on June 25, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.